Form 4: Twist Bioscience CEO Emily Leproust Reports Stock Transactions Following PSU Vesting
SEC Form 4 Filing
CEO Emily Leproust reports acquisition of shares through performance stock units and subsequent sale to cover tax obligations.
Summary
- Emily M. Leproust, CEO of Twist Bioscience Corp, reported transactions involving the company's common stock on November 4, 2024.
- She acquired 80,855 and 45,954 shares of common stock due to the vesting of performance stock units (PSUs) at a price of $0.
- Following these acquisitions, she sold 4,841 shares at $41.564 per share to cover tax withholding obligations related to the vesting of restricted stock units.
- After these transactions, Leproust directly owns 603,886 shares of Twist Bioscience common stock.
- She also holds options to purchase additional shares at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transactions are routine and related to compensation. The vesting of PSUs is a positive signal, but the sale to cover taxes is a neutral event.
Positives
- The vesting of performance stock units indicates that performance criteria were met, which could be viewed positively.
Negatives
- The sale of shares to cover tax obligations, while not discretionary, could be interpreted as a slight negative, although it's a common practice.
Risks
- The document itself doesn't highlight specific risks, but the value of the stock holdings is subject to market fluctuations.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Vesting schedules and performance-based equity awards are standard practices in the biotechnology industry, similar to companies like Illumina (ILMN) and Ginkgo Bioworks (DNA).
- The 'sell to cover' practice for tax obligations is a widespread method used by executives across various sectors, including those in the pharmaceutical and technology industries.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may view the vesting of PSUs as a positive sign of performance.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to one employee stock option vested. |
| 09/28/2017 | 10% of shares subject to one employee stock option vested. |
| 09/28/2018 | 15% of shares subject to one employee stock option vested. |
| 10/31/2019 | 20% of shares subject to one employee stock option vested. |
| 09/01/2020 | Performance stock options granted to the reporting person. |
| 10/24/2020 | 25% of shares subject to one employee stock option vested. |
| 12/19/2022 | Performance stock options vested and became exercisable. |
| 09/28/2025 | Expiration date of one employee stock option. |
| 10/01/2025 | 60% of the PSUs remain subject to time-based vesting and will vest on this date. |
| 09/28/2027 | Expiration date of one employee stock option. |
| 11/18/2028 | Expiration date of one employee stock option. |
| 10/23/2029 | Expiration date of one employee stock option. |
| 08/31/2030 | Expiration date of one employee stock option. |
| 11/04/2024 | Date of the reported transactions: PSU vesting and share sale. |
| 11/06/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.